Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Analyses of Minimal Residual Disease (MRD) Negativity Dynamics in the Phase 3 Imroz Study

Blood (2024) 144 (Supplement 1): 770.

https://doi.org/10.1182/blood-2024-203818

Published: 2024

Journal Articles

First-Line Ibrutinib Plus Venetoclax Vs Chlorambucil Plus Obinutuzumab in Elderly or Comorbid Patients (Pts) with Chronic Lymphocytic Leukemia (CLL): Glow Study 64-Month Follow-up (FU) and Adverse Event (AE)-Free Progression-Free Survival (PFS) Analysis

Blood (2024) 144 (Supplement 1): 1871.

https://doi.org/10.1182/blood-2024-203269

Published: 2024

Journal Articles

Health-Related Quality of Life (HRQoL) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplantation and Treated with Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) Vs. Vrd Alone: Results from the Imroz Study

Blood (2024) 144 (Supplement 1): 3352.

https://doi.org/10.1182/blood-2024-207087

Published: 2024

Journal Articles

First-Line Fixed-Duration Ibrutinib Plus Venetoclax (Ibr+Ven) Versus Chlorambucil Plus Obinutuzumab (Clb+O): 55-Month Follow-up from the Glow Study

Blood (2023) 142 (Supplement 1): 634.

https://doi.org/10.1182/blood-2023-177713

Published: 2023

Journal Articles

Residual Disease Kinetics Among Patients with High-Risk Factors Treated with First-Line Fixed-Duration Ibrutinib Plus Venetoclax (Ibr+Ven) Versus Chlorambucil Plus Obinutuzumab (Clb+O): The Glow Study

Blood (2022) 140 (Supplement 1): 228–230.

https://doi.org/10.1182/blood-2022-156070

Published: 2022

Journal Articles

Abatacept/Tacrolimus or Abatacept/Tacrolimus/Post-Transplant Cyclophosphamide Are Safe and Highly Effective in Preventing Graft-Versus-Host Disease in Matched or Mismatched Donor Peripheral Blood Stem Cell Transplantation

Vladimir I. Vorobyev, Anton Yu. Subora, Yulia A. Oleinik, Lev S. Butaev, Vera A. Zherebtsova, Darya G. Kisilichina, Margarita A. Ulyanova, Evdokiya S. Urnova, Alena M. Sukhareva, Matvei P. Bulusov

Blood (2022) 140 (Supplement 1): 7622–7623.

https://doi.org/10.1182/blood-2022-168542

Published: 2022

Journal Articles

Final Results of CHRONOS19 Observational Study in Patients with Hematologic Disease and COVID-19 in Russia

Blood (2021) 138 (Supplement 1): 4994.

https://doi.org/10.1182/blood-2021-152735

Published: 2021

Journal Articles

First Prospective Data on Minimal Residual Disease (MRD) Outcomes after Fixed-Duration Ibrutinib Plus Venetoclax (Ibr+Ven) Versus Chlorambucil Plus Obinutuzumab (Clb+O) for First-Line Treatment of CLL in Elderly or Unfit Patients: The Glow Study

Blood (2021) 138 (Supplement 1): 70.

https://doi.org/10.1182/blood-2021-148666

Published: 2021

Journal Articles

TEMPO: A Phase 2, Randomized, Open-Label, 2-Arm Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Subjects with Indolent Non Hodgkin Lymphoma (iNHL)

Vladimir I. Vorobyev, Dok Hyun Yoon, Maciej Kaźmierczak, Sebastian Grosicki, Corrado Tarella, Angelo Genua, Jin Seok Kim, Debra Litwak, David Cohan, Ian W. Flinn, Pier Luigi Zinzani, Leo I. Gordon

Blood (2021) 138 (Supplement 1): 3545.

https://doi.org/10.1182/blood-2021-147564

Published: 2021

Journal Articles

Outcomes in Patients with Hematologic Disease and COVID-19 in Russia: Interim Analysis of CHRONOS19 Registry

Blood (2020) 136 (Supplement 1): 41–42.

https://doi.org/10.1182/blood-2020-138504

Published: 2020

Journal Articles

Ibrutinib Monotherapy in Patients with Relapsed/Refractory Mantle Cell Lymphoma in Community Clinical Practice Outside of Clinical Trials

Vladimir I. Vorobyev, MD PhD, Vera A. Zherebtsova, MD PhD, Egor I. Dubrovin, Liudmila A. Bychenkova, Lev S. Butaev, Larisa A. Muha, Yulia B. Kochkareva, Valentina L. Ivanova, Eugene A. Nikitin, MD PhD Professor, Gayane Tumyan, DMSc, MD PhD, Vadim A Doronin, MD, Oleg I. Krijanovski, MD PhD, Vadim Ptushkin, MD PhD Professor

Blood (2019) 134 (Supplement_1): 5255.

https://doi.org/10.1182/blood-2019-126430

Published: 2019

Journal Articles

Randomized, Open-Label, Non-Inferiority, Phase 3 Study of Subcutaneous (SC) Versus Intravenous (IV) Daratumumab (DARA) Administration in Patients with Relapsed or Refractory Multiple Myeloma: Columba Update

Blood (2019) 134 (Supplement_1): 1865.

https://doi.org/10.1182/blood-2019-122765

Published: 2019

Journal Articles

Randomized, Open-Label, Non-Inferiority, Phase 3 Study of Subcutaneous (SC) Versus Intravenous (IV) Daratumumab (DARA) Administration in Patients (Pts) with Relapsed or Refractory Multiple Myeloma (RRMM): Body Weight Subgroup Analysis of Columba

Blood (2019) 134 (Supplement_1): 1906.

https://doi.org/10.1182/blood-2019-122501

Published: 2019

Journal Articles

B-Cell Lymphoma Unclassified, Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma: A Single Center Experience of Intensive Chemotherapy with and without Auto-SCT

Anna E. Lukina, MD PhD, Elena A. Baryakh, MD PhD, Alla M. Kovrigina, MD PhD Prof., Eduard G. Gemdzhian, PhD, Vsevolod A. Misyurin, PhD, Sergey K. Kravchenko, MD PhD, Vladimir I. Vorobyev, MD PhD, Jana K. Mangasarova, MD PhD, Aminat U. Magomedova, MD PhD, Yuri U. Polyakov, PhD, Tatiana N. Obukhova, PhD, Eugene E. Zvonkov, MD PhD, Anna K. Morozova, MD PhD, Valeri G. Savchenko, MD PhD Prof.

Blood (2014) 124 (21): 5902.

https://doi.org/10.1182/blood.V124.21.5902.5902

Published: 2014

Journal Articles

Front-Line High Dose Therapy with Following Autologous Stem Cell Transplantation (ASCT) for Follicular Lymphoma Patients

Ekaterina S. Nesterova, MD PhD, Sergey K. Kravchenko, MD PhD, Alla M. Kovrigina, MD PhD Prof., Eduard G. Gemdzhian, PhD, Aminat U. Magomedova, MD PhD, Elena A. Bariakh, MD PhD, Vladimir I. Vorobyev, MD PhD, Ekaterina A. Iliushkina, MD, Dmitry S. Mariin, MD, Natalia G. Chernova, MD PhD, Olga A. Gavrilina, MD, Anna E. Lukina, MD PhD, Valeri G. Savchenko, MD PhD Prof.

Blood (2014) 124 (21): 5908.

https://doi.org/10.1182/blood.V124.21.5908.5908

Published: 2014

Journal Articles

Less Toxic Gemcitabine-Oxaliplatin Based Induction Regimen (R-GIDIOX) Prior to Autologous SCT Produces Outcomes Similar to High-Dose Cytarabine Containing Intensive Induction Regimen in Mantle Cell Lymphoma – a Follow up Report of the Multicenter Study

Vladimir I. Vorobyev, MD PhD, Sergei K. Kravchenko, MD PhD, Eduard G. Gemdzhian, PhD, Jana K. Mangasarova, MD PhD, Elena Baryakh, MDPhD, Alla M. Kovrigina, MD PhD Prof., Tatiana N. Obukhova, PhD, Kamil Kaplanov, Egor I. Dubrovin, MD, Ivan A Vorobjev, Prof., Natalya G. Turina, MD PhD, Valeri G. Savchenko, MD Prof.

Blood (2014) 124 (21): 1726.

https://doi.org/10.1182/blood.V124.21.1726.1726

Published: 2014

Journal Articles

Long-Term Overall Survival In Diffuse Large B-Cell Lymphoma With Bone Marrow Involvement Patients After High-Dose Chemotherapy Plus Autologous Stem Cells Transplantation

Olga A. Gavrilina, MD, Evgeny E. Zvonkov, MD, PhD, Nelly G. Gabeeva, MD, PhD, Eduard G. Gemdjian, PhD, Vladimir I. Vorobyev, MD, Sergey K. Kravchenko, MD, PhD, Valeri G. Savchenko, MD, PhD

Blood (2013) 122 (21): 2169.

https://doi.org/10.1182/blood.V122.21.2169.2169

Published: 2013

Journal Articles

Treatment of Primary Bone Lymphoma with Intensive Chemotherapy

Anna Morozova, Eugene Zvonkov, Vasilii Mamonov, Alla M. Kovrigina, MD, PhD, Sergei Kravchenko, Yuri Lorie, Vladimir I. Vorobyev, MD, Ekaterina Penskaya, Eduard Gemdjian, Valeriy G Savchenko, MD, PhD

Blood (2012) 120 (21): 4874.

https://doi.org/10.1182/blood.V120.21.4874.4874

Published: 2012

Journal Articles

Intensive Induction, Autologous Stem Cell Transplantation and Rituximab Maintenance Has Changed Event Free Survival and Overall Survival in Mantle Cell Lymphoma Patients. Using Gemcitabine and Oxaliplatin in First Line Therapy

Vladimir I. Vorobyev, MD, Yuri Yu. Lorie, MD, PhD, Evgenii' E. Zvonkov, MD, PhD, Eduard G. Gemdjian, PhD, Aminat U. Magomedova, MD, PhD, Anait L. Melikyan, MD, PhD, Jana K. Mangasarova, MD, PhD, Elena O. Gribanova, MD, PhD, Vera A. Zherebtsova, MD, PhD, Sergey K. Kravchenko, MD, PhD, Valeri G. Savchenko, MD, PhD

Blood (2012) 120 (21): 2034.

https://doi.org/10.1182/blood.V120.21.2034.2034

Published: 2012

Journal Articles

T(11;14)(q13;q32) in Mantle Cell Lymphoma Patients Is Present Only on Mature Malignant Cells. Fluorescence-Activated Cell Sorting and Fluorescence in Situ Hybridization Analysis

Vladimir I. Vorobyev, MD, Evgenii’ M Gretsov, Tatyana N Obukhova, Elena V Domracheva, PhD, Yuri Yu Lorie, MD, Sergey K Kravchenko, MD, Ivan A Vorobjev, PhD

Blood (2011) 118 (21): 4405.

https://doi.org/10.1182/blood.V118.21.4405.4405

Published: 2011

NARROW

Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Analyses of Minimal Residual Disease (MRD) Negativity Dynamics in the Phase 3 Imroz Study

First-Line Ibrutinib Plus Venetoclax Vs Chlorambucil Plus Obinutuzumab in Elderly or Comorbid Patients (Pts) with Chronic Lymphocytic Leukemia (CLL): Glow Study 64-Month Follow-up (FU) and Adverse Event (AE)-Free Progression-Free Survival (PFS) Analysis

Health-Related Quality of Life (HRQoL) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplantation and Treated with Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) Vs. Vrd Alone: Results from the Imroz Study

First-Line Fixed-Duration Ibrutinib Plus Venetoclax (Ibr+Ven) Versus Chlorambucil Plus Obinutuzumab (Clb+O): 55-Month Follow-up from the Glow Study

Residual Disease Kinetics Among Patients with High-Risk Factors Treated with First-Line Fixed-Duration Ibrutinib Plus Venetoclax (Ibr+Ven) Versus Chlorambucil Plus Obinutuzumab (Clb+O): The Glow Study

Abatacept/Tacrolimus or Abatacept/Tacrolimus/Post-Transplant Cyclophosphamide Are Safe and Highly Effective in Preventing Graft-Versus-Host Disease in Matched or Mismatched Donor Peripheral Blood Stem Cell Transplantation

Final Results of CHRONOS19 Observational Study in Patients with Hematologic Disease and COVID-19 in Russia

First Prospective Data on Minimal Residual Disease (MRD) Outcomes after Fixed-Duration Ibrutinib Plus Venetoclax (Ibr+Ven) Versus Chlorambucil Plus Obinutuzumab (Clb+O) for First-Line Treatment of CLL in Elderly or Unfit Patients: The Glow Study

TEMPO: A Phase 2, Randomized, Open-Label, 2-Arm Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Subjects with Indolent Non Hodgkin Lymphoma (iNHL)

Outcomes in Patients with Hematologic Disease and COVID-19 in Russia: Interim Analysis of CHRONOS19 Registry

Ibrutinib Monotherapy in Patients with Relapsed/Refractory Mantle Cell Lymphoma in Community Clinical Practice Outside of Clinical Trials

Randomized, Open-Label, Non-Inferiority, Phase 3 Study of Subcutaneous (SC) Versus Intravenous (IV) Daratumumab (DARA) Administration in Patients with Relapsed or Refractory Multiple Myeloma: Columba Update

Randomized, Open-Label, Non-Inferiority, Phase 3 Study of Subcutaneous (SC) Versus Intravenous (IV) Daratumumab (DARA) Administration in Patients (Pts) with Relapsed or Refractory Multiple Myeloma (RRMM): Body Weight Subgroup Analysis of Columba

B-Cell Lymphoma Unclassified, Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma: A Single Center Experience of Intensive Chemotherapy with and without Auto-SCT

Front-Line High Dose Therapy with Following Autologous Stem Cell Transplantation (ASCT) for Follicular Lymphoma Patients

Less Toxic Gemcitabine-Oxaliplatin Based Induction Regimen (R-GIDIOX) Prior to Autologous SCT Produces Outcomes Similar to High-Dose Cytarabine Containing Intensive Induction Regimen in Mantle Cell Lymphoma – a Follow up Report of the Multicenter Study

Long-Term Overall Survival In Diffuse Large B-Cell Lymphoma With Bone Marrow Involvement Patients After High-Dose Chemotherapy Plus Autologous Stem Cells Transplantation

Treatment of Primary Bone Lymphoma with Intensive Chemotherapy

Intensive Induction, Autologous Stem Cell Transplantation and Rituximab Maintenance Has Changed Event Free Survival and Overall Survival in Mantle Cell Lymphoma Patients. Using Gemcitabine and Oxaliplatin in First Line Therapy

T(11;14)(q13;q32) in Mantle Cell Lymphoma Patients Is Present Only on Mature Malignant Cells. Fluorescence-Activated Cell Sorting and Fluorescence in Situ Hybridization Analysis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only